Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 75340L104 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Bain Capital Life Sciences Fund, L.P.
13G/A
|
16.8% |
8/14/2026
Event 6/30/2026
|
|
| Bain Capital Life Sciences Fund, L.P. | 16.8% | ||
| BCIP Life Sciences Associates, LP | 1.7% | ||
|
Longitude Capital Partners II, LLC
13G/A
|
8.6% |
5/15/2026
Event 3/31/2026
|
|
| Longitude Capital Partners II, LLC | 8.6% | ||
| Longitude Venture Partners II, L.P. | 8.6% | ||
| Longitude Prime Partners, LLC | 0% | ||
| Longitude Prime Fund, L.P. | 0% | ||
| Patrick G. Enright | 8.6% | ||
| Juliet Tammenoms Bakker | 8.6% | ||
|
Armistice Capital, LLC
13G
|
7.3% |
8/14/2026
Event 6/30/2026
|
|
| Armistice Capital, LLC | 7.3% | ||
| Steven Boyd | 7.3% | ||
| Spignesi Robert G. Jr. 13D | 6.3% |
8/19/2025
Event 3/28/2024
|
|
|
Endeavour Medtech Growth II LP
13G/A
|
5.7% |
2/13/2026
Event 12/31/2025
|
|
| Endeavour Medtech Growth II LP | 5.7% | ||
| Endeavour Medtech Growth II Parallel LP | 5.7% | ||
| Endeavour Medtech II GP Limited | 5.7% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 34 | 17.5 M | $30.3 M |
| 2026 Q1 | 46 | 15.8 M | $36.0 M |
| 2025 Q4 | 42 | 14.6 M | $42.5 M |
| 2025 Q3 | 30 | 14.8 M | $49.5 M |
| 2025 Q2 | 30 | 15.1 M | $52.3 M |
| 2025 Q1 | 29 | 15.3 M | $40.4 M |
| 2024 Q4 | 20 | 11.9 M | $10.8 M |
| 2024 Q3 | 21 | 17.9 M | $15.9 M |
| 2024 Q2 | 24 | 19.1 M | $12.6 M |
| 2024 Q1 | 27 | 19.7 M | $18.9 M |
| 2023 Q4 | 30 | 21.1 M | $15.6 M |
| 2023 Q3 | 24 | 21.5 M | $23.2 M |
| 2023 Q2 | 25 | 21.9 M | $21.9 M |
| 2023 Q1 | 32 | 22.9 M | $34.5 M |
| 2022 Q4 | 44 | 24.5 M | $27.7 M |
| 2022 Q3 | 54 | 25.6 M | $82.8 M |
| 2022 Q2 | 53 | 26.1 M | $112 M |
| 2022 Q1 | 61 | 26.7 M | $181 M |
| 2021 Q4 | 57 | 21.8 M | $232 M |
| 2021 Q3 | 50 | 21.8 M | $401 M |